DNA methyltransferase inhibitors: old and new drugs for an epigenetic cancer therapy
Bodo Brueckner, Frank Lyko
págs. 551-554
Not all progestins are the same: implications for usage
Janet P. Hapgood, Ann Louw, Donita Africander, Dominique Koubovec
págs. 554-557
Is JAK3 a new drug target for immunomodulation-based therapies?
Anastassios C. Papageorgiou, Linnea E.K. Wikman
págs. 558-562
Mast cells as targets of corticotropin-releasing factor and related peptides
Theoharis C. Theoharides, Jill M. Donelan, Duraisamy Kempuraj, Jing Cao, Nikoletta Papadopoulou, Pio Conti
págs. 563-568
Auralyn J. Mackenzie, Domenico Spina, Clive P. Page, Sandra M. Reynolds
págs. 569-576
Erythropoietin in the brain: can the promise to protect be fulfilled?
Kenneth Maiese, Faqi Li, Zhao Zhong Chong
págs. 577-583
Na<sup>+</sup> channel expression along axons in multiple sclerosis and its models
Matthew J. Craner, Joel A. Black, Stephen G. Waxman
págs. 584-591
Pharmacological interventions in ventilator-induced lung injury
Stefan Uhlig, Ulrike Uhlig
págs. 592-600
The TREK K<sub>2P</sub> channels and their role in general anaesthesia and neuroprotection
Eric Honoré, Nicholas P. Franks
págs. 601-608
© 2001-2024 Fundación Dialnet · Todos los derechos reservados